Elevated Triglycerides in Major Depressive Disorder: A Metabolic Signal We Should Not Ignore
Major depressive disorder (MDD) is increasingly recognized not only as a disorder of mood, but also as a condition involving systemic biological changes. While much attention has focused on inflammation, neurocircuitry, and neurotransmitters, metabolic markers—particularly lipid abnormalities—may provide important additional insight into the biology of depression.
In a recent study published in Lipids (2026), our team, in close collaboration with Brazilian research partners, examined the relationship between lipid profile parameters and psychiatric symptoms in individuals with MDD. As one of the co-authors of this work, I am particularly encouraged by what the findings suggest: elevated triglyceride levels may represent a clinically meaningful metabolic signature in major depressive disorder.
This international collaboration reflects a growing effort to bridge biological psychiatry and metabolic science across institutions and countries.
Why This Study Matters
Patients with MDD experience significantly higher rates of cardiovascular disease, metabolic syndrome, and premature mortality. However, the relationship between depression and lipid metabolism remains incompletely understood.
This study advanced the field by integrating:
- Lipid profile analysis
- Functional impairment assessment
- Anxiety and depression severity scales
- Stress evaluation
- Biological rhythm disruption
This multidimensional approach allows for a more comprehensive understanding of how metabolic changes intersect with the clinical expression of depression.
Study Overview
- Design: Cross-sectional clinical study
- Participants: 160 individuals (31 with MDD, 129 controls)
- Assessments included:
- MINI-Plus diagnostic interview
- Hamilton Depression (HAM-D) and Anxiety (HAM-A) scales
- Functional Assessment Short Test (FAST)
- Biological Rhythms Interview of Assessment in Neuropsychiatry (BRIAN)
- Stress symptom inventory
- Fasting lipid profile (triglycerides, total cholesterol, HDL-C, LDL-C)
There were no significant demographic differences between groups, thereby strengthening the reliability of the findings.
Key Findings
- Clear Clinical Burden in MDD
Individuals with MDD demonstrated:
- Greater functional impairment
- Higher depressive and anxious symptom severity
- Elevated stress levels
- More pronounced disruption in biological rhythms
These findings reinforce the multidimensional impact of depression beyond mood symptoms alone.
- Triglycerides Were Significantly Elevated
The most notable metabolic finding was:
- Higher triglyceride (TG) levels in individuals with MDD
- No significant differences in total cholesterol, HDL-C, or LDL-C
This selective hypertriglyceridemia suggests that triglycerides may represent a more sensitive metabolic marker in depression compared to traditional cholesterol fractions.
- Lipids and Clinical Correlations
While triglycerides were elevated, correlations with symptom severity were limited. This suggests that triglyceride elevation may reflect:
- An underlying biological vulnerability
- A parallel metabolic dysregulation process
- A systemic feature of depressive illness rather than merely a consequence of symptom intensity
Biological Interpretation
Triglycerides are closely linked to:
- Inflammation
- Insulin resistance
- HPA axis dysregulation
- Oxidative stress
- Neuroinflammatory signaling
These pathways overlap significantly with contemporary models of depression pathophysiology. The integration of metabolic and psychiatric research—across international collaborations such as this one—represents an important step toward understanding depression as a systemic disorder.
Clinical Implications
This study reinforces a critical message:
Depression is not only a brain disorder—it is a whole-body disorder.
For clinicians, this means:
- Routine metabolic monitoring in MDD is essential
- Elevated triglycerides should not be dismissed as incidental
- Lifestyle and metabolic interventions may play an adjunctive role
- Integrated psychiatric and medical care models are necessary
Given the elevated cardiovascular risk in MDD, triglyceride elevation may serve as both a psychiatric biomarker and a cardiometabolic warning signal.
Looking Ahead
Future research should examine:
- Longitudinal changes in triglycerides over the course of depressive episodes
- Whether triglyceride reduction improves psychiatric outcomes
- Mechanistic links between lipid metabolism and neuroinflammation
- The role of metabolic stratification in treatment-resistant depression
International collaboration remains essential as we work toward biologically informed, precision-based psychiatry.
Reference
Meirelles SS, Arent CO, Pedro LC, et al. Elevated triglyceride levels and increased psychiatric symptoms in individuals with major depressive disorder. Lipids. 2026;0:1–9.
Contact
- Request for Second Opinion Form: https://Go.uth.edu/CIPIntake (external link)
- Phone: (713) 486-2621
- Fax: (713) 500-2728
- E-mail: [email protected]
Disclaimer
This article was created with the assistance of artificial intelligence (AI) to support clarity and readability. All medical and scientific content has been reviewed and approved by Joao L. de Quevedo, MD, PhD, Director of the Center for Interventional Psychiatry at the John S. Dunn Behavioral Sciences Center at UTHealth Houston. This content is for educational purposes only and does not substitute for professional medical advice.